Drug
PEG-l-asparaginase
PEG-l-asparaginase is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)
Phase Distribution
Ph early_phase_1
1
25%
Ph phase_2
2
50%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Early Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
completed250%
terminated250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
NCT01117441
terminatedphase_2
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
NCT02419755
terminatedearly_phase_1
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
NCT01878708
completedphase_2
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
NCT00905034
Clinical Trials (4)
Showing 4 of 4 trials
NCT01117441Phase 3
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
NCT02419755Phase 2
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
NCT01878708Early Phase 1
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
NCT00905034Phase 2
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4